FDA CDER Impact Story: Improving the Design of Clinical Trials of Drugs to Treat Schizophrenia - Drug Information Update

U.S. Food and Drug Administration sent this bulletin at 11/12/2020 10:30 AM EST

If your email program has trouble displaying this email, view it as a web page.

FDA Center for Drug Evaluation and Research Division of Drug Information

FDA CDER Impact Story: Improving the Design of Clinical Trials of Drugs to Treat Schizophrenia

Demonstrating the efficacy of candidate drugs to treat schizophrenia can be especially challenging, but CDER scientists are uniquely positioned to explore ways to make trials of schizophrenia drugs more efficient, sensitive, and cost-effective.

Learn More

This is an automated message delivery system. Replying to this message will not reach DDI staff. If you have comments or questions, please contact us at: 1-888-INFO- FDA (1-888-463-6332) or 301-796-3400 from 8:00 am - 4:30 pm ET Monday - Friday. You can also email us at: druginfo@fda.hhs.gov.